Investing.com - Cytokinetics Inc (NASDAQ: CYTK) reported fourth quarter EPS of $-1.38, $0.42 worse than the analyst estimate of $-0.96. Revenue for the quarter came in at $1.67M versus the consensus estimate of $7.63M.
Guidance
Cytokinetics Inc sees FY 2024 revenue of $3.00M-$5.00M versus the analyst consensus of $26.24M.
Cytokinetics Inc's stock price closed at $80.99. It is up 141.26% in the last 3 months and up 86.79% in the last 12 months.
Cytokinetics Inc saw 1 positive EPS revisions and 10 negative EPS revisions in the last 90 days. See Cytokinetics Inc's stock price’s past reactions to earnings here.
According to InvestingPro, Cytokinetics Inc's Financial Health score is "weak performance".
Check out Cytokinetics Inc's recent earnings performance, and Cytokinetics Inc's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar